MARATTO

article · Discover Pharmaceutical Sciences

Insilico, network pharmacology and neural network studies on Sida acuta Burm f.- based phytochemicals targeting NADH-ubiquinone oxidoreductase

20253 citationsOpen accessOsun State University

Abstract

The biochemical activities of phytochemicals obtained from S. acuta Burm f. have been described in several forms by various scientists globally. This work has revealed the antimalarial activities of S. acuta Burm f. using various methods such as density functional theory method, induced fit docking technique, quantitative structure activities relationship (QSAR) via neural network approach and pharmacokinetics studies using ADMETLab software. Compound F10 showed a stronger ability to interact in terms of HOMO energy and energy gap while Compound F12 exhibited a high tendency to accept electrons from nearby compounds. Furthermore, compound F13 demonstrated greater potential to inhibit NADH-Ubiquinone Oxidoreductase. We observed that the derivatives in F10, F12 and F13 enhanced the reactivity and inhibiting activities of the parent compound. The prediction of binding affinity for compounds F1 to F16 using neural network was found to be accurate and dependable. Also, ADMET study was executed and reported appropriately. Our research could pave the way for the creation of a library of effective phytochemicals from S. acuta Burm f -based drugs with potential anti-malaria activity.

Research topics

  • Medicinal Plants and Neuroprotection
  • Natural Antidiabetic Agents Studies
  • Ethnobotanical and Medicinal Plants Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1007/s44395-025-00002-8

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.